
AI-enabled Stroke Prediction in Patients with Chronic Kidney DiseaseAward last edited on: 5/19/2023
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$240,053Award Phase
1Solicitation Topic Code
837Principal Investigator
Waqaas Al-SiddiqCompany Information
Biotricity Inc (AKA: Metasolutions Inc)
203 Redwood Shores Parkway Suite 600
Redwood City, CA 94065
Redwood City, CA 94065
(650) 832-1626 |
info@biotricity.com |
www.biotricity.com |
Location: Single
Congr. District: 15
County: San Mateo
Congr. District: 15
County: San Mateo
Phase I
Contract Number: 1R43HL161759-01A1Start Date: 9/1/2022 Completed: 8/31/2023
Phase I year
2022Phase I Amount
$240,053Public Health Relevance Statement:
PROJECT NARRATIVE Chronic Kidney Disease (CKD) is associated with a high risk of both ischemic and hemorrhagic strokes, a three-fold mortality rate and five-fold healthcare spending. Real-time monitoring of the stroke risk in CKD patients could support optimal therapeutic strategies and promote a more personalized therapeutic approach. Biotricity is developing Bioflux-AI, an innovative system for real-time monitoring and prediction of stroke episodes in CKD patients, combining an FDA-approved, high-precision, small mobile cardiac telemetry (MCT) device with AI- driven algorithms specifically trained for the prediction of stroke in CKD patients.
Project Terms:
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00